From a record-setting Life Sciences fund to growth rounds in AI and neurotech, this week’s MedTech deals are fueling clinical validation and global expansion. Details follow below.
Blackstone announces final close of $6.3B Life Sciences Fund
BXLS VI was oversubscribed and closed at its hard cap of $6.3B of total capital commitments. It is the largest life sciences private fund ever raised and is nearly 40% larger than its predecessor vehicle.
BXLS has committed nearly $2B in new investments over the past 12 months.
Co-Founder and CEO Stephen Schwarzman
Last week’s tracker: Endogenex, Vaxess & more
Diagens Biotechnology raises $101M in Hong Kong IPO
The IPO raised approximately $101M through the sale of 7,999,200 H shares. The public offer tranche was 1,073 times oversubscribed.
Huatai Financial Holdings (Hong Kong) acted as sole sponsor.
CEO Song Ning
StairMed raises $73М to advance BMI and DBS system development
The financing round was led by Alibaba. Existing investors including Tencent, Fountainbridge Capital, OrbiMed, Oriza Seed, and Source Code Capital also participated.
The latest funding round brings the company’s total funds raised in the past year to over RMB 1.1B ($160M).
Founder Li Xue
Mediwhale secures $13.1M in Series C funding, preparing for IPO
Premier Partners led the investment, with KB Investment, Quad Investment Management, IMM Investment, Hana Ventures, AON Investment, and Startup Partners joining. Mediwhale’s total funding now stands at about 51.2B won.
The company plans to fully invest the funds into expanding the Korean and foreign markets for Doctor Noon CVD, pursuing clinical trials and regulatory approvals in the U.S. and globally.
CEO Kevin Choi
Lucida Medical raises £8.7M to power ‘same day’ cancer diagnosis
The funding round was led by IW Capital, with participation from existing investors, XTX Ventures and Macmillan Cancer Support.
The investment is into patented AI software designed to support earlier and more consistent cancer detection in minutes, not weeks.
Co-Founder and CEO Antony Rix
Lifebloom raised €8M to launch its Lifebloom One solution
The company secured €6M in capital from a consortium of family offices, entrepreneurs, and private investors to launch the industrialization of its Lifebloom One solution.
A €2M grant from the French government’s France 2030 plan brings the total funding to €8M.
Founder and CEO Damien Roche
Neurolief raises $6M to fuel US rollout of Proliv Rx
The investment was led by BrainsWay, a MedTech company based in Israel and a leader in noninvasive neurostimulation.
The funding will accelerate the U.S. rollout of Proliv Rx, expanding the reach of neuromodulation beyond the confines of the clinic.
CEO Scott Drees
Acurion closes oversubscribed $4.3M Seed round
The round was led by TK & Partners, with participation from Mesa Verde Venture Partners, The National Foundation for Cancer Research and the Asian Fund for Cancer Research, Bootstrap Ventures, and institutional investors.
The financing will further support clinical validation, platform development, regulatory preparation, and commercialization as Acurion advances OncoGaze toward broader clinical and research adoption.
CEO Rick Fultz
Echopoint Medical secures $2.5M funding round
The funding will support the company as it advances towards FDA submission and launches its US clinical programme, generating real-world evidence for its technology.
The investment round was led by Parkwalk, with participation from UCL Technology Fund.
CEO Antony Odell
Sub-Q Bionics closes $1.5M Pre-Seed round
The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds.
The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed.
CEO Jordan Pollack
KOEDA secures funding to develop its organ-fixation anchor
The funds raised will be directed toward a domestic confirmatory clinical trial, regulatory approval applications and QMS strengthening, and preparations for expansion into the US.
The round includes the new investor Mitsubishi UFJ Capital as well as a follow-on investment from the existing investor Tohoku University Venture Partners.
CEO Toru Okuzono
